28 Mar, 2018 New Clinical Results from APOLLO Phase 3 Study of Patisiran at ISA
We presented additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the 16th International Symposium on Amyloidosis (ISA), held March 26-29, 2018 in Kumamoto, Japan.
Kristen et al. – “APOLLO, a Phase 3 Study of Patisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis: 18-Month Safety and Efficacy in Subgroup of Patients with Cardiac Involvement”
Polydefkis et al. – “Relationship Between Transthyretin Knockdown and Change in mNIS+7: Findings from the Patisiran Phase 2 Open-Label Extension and Phase 3 APOLLO Studies for Patients with Hereditary Transthyretin-Mediated Amyloidosis”
Gonzalez-Duarte et al. – “Changes in Neuropathy Stage in Patients with Hereditary Transthyretin-Mediated Amyloidosis Following Treatment with Patisiran, an Investigational RNAi Therapeutic: An Analysis from the Phase 3 APOLLO Study”
Suhr et al. – “Long-Term Use of Patisiran, an Investigational RNAi Therapeutic, in Patients with Hereditary Transthyretin-Mediated Amyloidosis: Baseline Demographics and Interim Data from Global Open Label Extension Study”
In addition, we presented new data from the Phase 1 study of ALN-TTRsc02, an investigational, subcutaneously administered RNAi therapeutic for the treatment of ATTR amyloidosis.